KMT2A and acute myeloid leukemia: To begin to explore the possible utility of small-molecule CGRP antagonists for the treatment of AML, a mouse model was used in which AML is driven by MLL-AF9 (MA9), a leukemogenic fusion gene recurrently found in human AML [48,49,50].